NEWS

Muvon

10 hours ago2 min read

MUVON Completes Patient Enrollment of Randomized Phase 2 Clinical Study Evaluating Muscle Precursor Cell (MPC)-based Therapy in Stress Urinary Incontinence and Expects Topline Data in Q3 2025

UVON Therapeutics AG, an innovative clinical-stage biotechnology company, announces dosing of the last patient in its phase 2 clinical study.

Muvon

Jan 92 min read

MUVON Therapeutics Clears Phase 2 Interim Milestone and Will Participate in the 2025 J.P. Morgan Healthcare Conference

Muvon

Nov 12, 20241 min read

MUVON featured in PharmaBoardroom Interview

Muvon

Oct 28, 20242 min read

MUVON Therapeutics announces appointments to its Advisory Board.

Muvon

Jul 30, 20242 min read

Muvon Therapeutics announces the appointment of Marcus Droege as Chief Commercial Officer

Muvon

Jun 10, 20241 min read

MUVON featured by founded.ch

Muvon

May 31, 20241 min read

MUVON featured by Nature Biotechnology

Muvon

Dec 12, 20230 min read

MUVON Minute: First manifesto for SUI policy reform signed

Muvon

Dec 7, 20231 min read

Ladies Drive Interview with Deana Mohr & Jenny Prange on Female Innovator of the Year Award

Muvon

Sep 26, 20232 min read

MUVON joins EAU’s Urge to Act campaign during Urology Week

Muvon

Sep 22, 20231 min read

Deana Mohr and Jenny Prange win Female Innovator of the Year Award

Muvon

Sep 12, 20231 min read

MUVON's CEO & CTO nominated for Female Innovator of the Year Award

Muvon

Sep 7, 20231 min read

MUVON enters TOP 100 SWISS STARTUPS list as a top 3 Biotech

Muvon

Jun 12, 20231 min read

MUVON Therapeutics AG among the TOP 3 Swiss biotech leaders according to public voting

Muvon

Jun 2, 20231 min read

MUVON finishes as Top 3 finalist for the ZKB Pionierpreis 2023 with our tissue engineering therapy

Muvon

Apr 24, 20231 min read

First in Human trial results published, demonstrating safety and feasibility of MUVON's SUI Therapy

Muvon

Feb 6, 20231 min read

MUVON Therapeutics nominated as finalist for 2023 ZKB Pionierpreis

Muvon

Dec 22, 20221 min read

The leadership from MUVON Therapeutics AG will be attending JP Morgan Healthcare week in Jan 2023

Muvon

Nov 16, 20223 min read

MUVON Therapeutics announces appointments to its Board of Directors and Scientific Advisory Board

Muvon

Oct 27, 20223 min read

Muvon Therapeutics Announces First Patient Enrolled in Phase II Clinical Study

INVEST IN OUR
INNOVATION

MORE INFORMATION

Invest in us to be part of a groundbreaking journey toward innovative, life-changing muscle regeneration therapies, addressing a massive global market with scalable solutions.

MUVON Completes Patient Enrollment of Randomized Phase 2 Clinical Study Evaluating Muscle Precursor Cell (MPC)-based Therapy in Stress Urinary Incontinence and Expects Topline Data in Q3 2025

MUVON Therapeutics Clears Phase 2 Interim Milestone and Will Participate in the 2025 J.P. Morgan Healthcare Conference

MUVON featured in PharmaBoardroom Interview

MUVON Therapeutics announces appointments to its Advisory Board.

Muvon Therapeutics announces the appointment of Marcus Droege as Chief Commercial Officer

MUVON featured by founded.ch

MUVON featured by Nature Biotechnology

MUVON Minute: First manifesto for SUI policy reform signed

Ladies Drive Interview with Deana Mohr & Jenny Prange on Female Innovator of the Year Award

MUVON joins EAU’s Urge to Act campaign during Urology Week

Deana Mohr and Jenny Prange win Female Innovator of the Year Award

MUVON's CEO & CTO nominated for Female Innovator of the Year Award

MUVON enters TOP 100 SWISS STARTUPS list as a top 3 Biotech

MUVON Therapeutics AG among the TOP 3 Swiss biotech leaders according to public voting

MUVON finishes as Top 3 finalist for the ZKB Pionierpreis 2023 with our tissue engineering therapy

First in Human trial results published, demonstrating safety and feasibility of MUVON's SUI Therapy

MUVON Therapeutics nominated as finalist for 2023 ZKB Pionierpreis

The leadership from MUVON Therapeutics AG will be attending JP Morgan Healthcare week in Jan 2023

MUVON Therapeutics announces appointments to its Board of Directors and Scientific Advisory Board

Muvon Therapeutics Announces First Patient Enrolled in Phase II Clinical Study

INVEST IN OUR
INNOVATION

Invest in us to be part of a groundbreaking journey toward innovative, life-changing muscle regeneration therapies, addressing a massive global market with scalable solutions.

LINKS

ABOUT

SOCIAL

MUVON Completes Patient Enrollment of Randomized Phase 2 Clinical Study Evaluating Muscle Precursor Cell (MPC)-based Therapy in Stress Urinary Incontinence and Expects Topline Data in Q3 2025

MUVON Therapeutics Clears Phase 2 Interim Milestone and Will Participate in the 2025 J.P. Morgan Healthcare Conference

MUVON featured in PharmaBoardroom Interview

MUVON Therapeutics announces appointments to its Advisory Board.

Muvon Therapeutics announces the appointment of Marcus Droege as Chief Commercial Officer

MUVON featured by founded.ch

MUVON featured by Nature Biotechnology

MUVON Minute: First manifesto for SUI policy reform signed

Ladies Drive Interview with Deana Mohr & Jenny Prange on Female Innovator of the Year Award

MUVON joins EAU’s Urge to Act campaign during Urology Week

Deana Mohr and Jenny Prange win Female Innovator of the Year Award

MUVON's CEO & CTO nominated for Female Innovator of the Year Award

MUVON enters TOP 100 SWISS STARTUPS list as a top 3 Biotech

MUVON Therapeutics AG among the TOP 3 Swiss biotech leaders according to public voting

MUVON finishes as Top 3 finalist for the ZKB Pionierpreis 2023 with our tissue engineering therapy

First in Human trial results published, demonstrating safety and feasibility of MUVON's SUI Therapy

MUVON Therapeutics nominated as finalist for 2023 ZKB Pionierpreis

The leadership from MUVON Therapeutics AG will be attending JP Morgan Healthcare week in Jan 2023

MUVON Therapeutics announces appointments to its Board of Directors and Scientific Advisory Board

Muvon Therapeutics Announces First Patient Enrolled in Phase II Clinical Study

INVEST IN OUR INNOVATION

Invest in us to be part of a groundbreaking journey toward innovative, life-changing muscle regeneration therapies, addressing a massive global market with scalable solutions.

LINKS

ABOUT

SOCIAL

INVEST IN OUR
INNOVATION